19 July company SOPHiA GENETICS, offering a data-driven SaaS platform for the healthcare industry, announced the terms of the upcoming IPO.
The company is headquartered in Saint-Sulpice, Switzerland plans to attract 234 million dollars, releasing 13 million shares at a price of 17 to 19 dollars. Yet 20 million dollars the company plans to raise as part of a parallel private placement for a subsidiary of GE Healthcare. Taking into account the average price of the declared range, the total diluted market value of SOPHiA GENETICS will be 1,2 billion dollars.
SOPHiA GENETICS offers a cloud-based software-as-a-service platform (SaaS), able to analyze data and generate conclusions based on complex multimodal datasets and various diagnostic methods. IN 2014 year the company began to apply its platform for cancer diagnostics based on the analysis of next generation sequencing data (NGS). As of 31 Martha 2021 the platform included about 240 applications, used by health care providers, clinical and biological research laboratories and biopharmaceutical companies, specializing in precision medicine in the field of oncology, rare and infectious diseases, cardiology, neurology, metabolism and other diseases.
SOPHiA GENETICS was founded in 2011 year, and for 12 months, ended 31 Martha 2021 of the year, its revenue was 30 million dollars. The company plans to list on the stock exchange Nasdaq under the ticker SOPH. J.P.. Morgan, Morgan Stanley, Cowen и Credit Suisse. The company plans to hold an IPO this week, beginning with 22 july 2021 of the year.